African-Amercans’ heart drug

Sibbald, Barbara
August 2005
CMAJ: Canadian Medical Association Journal;8/2/2005, Vol. 173 Issue 3, p243
Academic Journal
Reports on the approval given by the U.S. Food and Drug Administration to the first drug ever intended for African-Americans with heart failure. Types of drugs included in the trial; Reason for aborting the trial in July 2004.


Related Articles

  • "Ethnic Drugs". Kahn, Jonathan // Hastings Center Report;Jan/Feb2005, Vol. 35 Issue 1, p49 

    Explores issues concerning BiDil, the first drug ever approved by the U.S. Food & Drug Administration to treat heart failure in African Americans. Findings of clinical trial of the drug; Explanation on race-specific labeling; Result of marketing of a race-specific drug.

  • BiDil: Assessing a Race-Based Pharmaceutical. Brody, Howard; Hunt, Linda M. // Annals of Family Medicine;Nov/Dec2006, Vol. 4 Issue 6, p556 

    The article offers information regarding the isosorbide and hydralazine in a fixed-dose combination BiDil. BiDil has provoked controversy as the first drug approved by the U.S. Food and Drug Administration marketed for a single racial-ethnic group, the African Americans. The drug is used in the...

  • New heart-failure therapy takes race into account. Thompson, Cheryl A. // American Journal of Health-System Pharmacy;9/1/2005, Vol. 62 Issue 17, p1745 

    Reports that the United States Food and Drug Administration has approved the marketing of NitroMed Inc.'s heart-failure combination drug BiDil which is expressly for use in patients who identify themselves as black and need additional therapy. Combination of isosorbide dinitrate and hydralazine...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk. Elliott, William T. // Clinical Cardiology Alert;Jul2007 Pharmacology Watch, p1 

    The article reports on a black box warning that will be receive by GlaxoSmithKline's rosiglitazone (Avandia) from the U.S. Food & Drug Administration (FDA) because of concerns over heart failure associated with use of the drug. The other drug that will be subjected to a black box warning is...

  • EchoCRT trial will eye CRT in those with narrow QRS.  // Medical Device Daily;5/20/2008, Vol. 12 Issue 97, p5 

    The article reports on the approval given by the U.S. Food and Drug Administration (FDA) to Biotronik to begin an international, prospective, randomized, controlled clinical trial to investigate the use of cardiac resynchronization therapy (CRT) in heart failure (HF) patients with left...

  • FDA Changes Course on Phase III Vasogen Study. Young, Donna // BioWorld Today;3/4/2008, Vol. 19 Issue 43, p1 

    The article reports that Vasogen Inc.'s shares dropped after the U.S. Food and Drug Administration (FDA) raised concerns about the design of the firms confirmatory Phase III clinical trial of Celacade, an investigational device to treat heart failure. The results from that Phase III trial showed...

  • Aldagen Adds $9M To Series C Financing.  // Bioworld Week;9/17/2007, Vol. 15 Issue 38, p5 

    The article reports that Aldagen Inc. has got an additional $9m in Series C financing, bringing its total financing to $23m for early stage clinical trials for its first three cell therapy products. Aldagen's Series C initially collected $14.3m in December 2006. The company is preparing to...

  • FDA panel votes no on heart-monitoring device.  // Modern Healthcare;12/12/2011, Vol. 41 Issue 50, p4 

    The article focuses on the decision of a U.S. Food and Drug Administration (FDA) advisory panel to vote against approving CardioMems' wireless, permanently implantable device that would allow cardiologists to remotely monitor heart-failure patients.

  • Odds still favor Novartis heart failure drug Serelaxin. Ratner, Mark // Nature Biotechnology;Jul2014, Vol. 32 Issue 7, p602 

    The article focuses on the rejection of an investigational drug Serelaxin manufactured by the pharmaceutical firm Novartis, by the U.S. Food and Drug Administration (FDA) after the controversies related to the confounding trial of the drug. It mentions the positive response in favor of the drug...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics